AI TextQuick Glance (AI)Headnote
Issues: (i) Whether, for A.Y. 2016-17, weighted deduction for expenditure on an approved in-house R&D facility could be restricted to the amount quantified by DSIR in Form 3CL; (ii) Whether the balance 50% of additional depreciation on eligible assets used for less than 180 days could be claimed in the immediately succeeding year; (iii) Whether, under Rule 8D, average total assets could be computed using written down value of fixed assets and net current assets; (iv) Whether, for A.Ys. 2017-18 and 2018-19, DSIR quantification in Form 3CL bound the tax authorities for weighted deduction, and whether unapproved expenditure could independently qualify under other scientific-research deduction provisions.
Issue (i): Whether, for A.Y. 2016-17, weighted deduction for expenditure on an approved in-house R&D facility could be restricted to the amount quantified by DSIR in Form 3CL.
Analysis: As applicable to A.Y. 2016-17, section 35(2AB) and Rule 6(7A) required approval of the in-house R&D facility, not DSIR certification of each item or quantum of expenditure. The facility held valid approval, and the genuineness and scientific-research nexus of the expenditure were not disputed. The subsequent requirement for DSIR quantification imposed an additional condition and operated prospectively.
Conclusion: For A.Y. 2016-17, the deduction could not be restricted merely to the amount stated in Form 3CL; the finding is in favour of the assessee.
Issue (ii): Whether the balance 50% of additional depreciation on eligible assets used for less than 180 days could be claimed in the immediately succeeding year.
Analysis: Section 32(1)(iia) conferred a one-time incentive, while the second proviso to section 32(1) restricted allowance in the acquisition year where use was below 180 days. That restriction did not extinguish the remaining entitlement. The third proviso applicable from A.Y. 2016-17 expressly allowed the balance in the succeeding year and was consistent with the beneficial object of additional depreciation.
Conclusion: The balance 50% additional depreciation was allowable in the immediately succeeding year; the finding is in favour of the assessee.
Issue (iii): Whether, under Rule 8D, average total assets could be computed using written down value of fixed assets and net current assets.
Analysis: Rule 8D(2)(ii) prescribes the average of total assets as appearing in the balance sheet. Its formula does not permit replacement of gross asset figures with written down values or reduction of current assets by current liabilities. Such substitutions reduce the denominator and impermissibly inflate the disallowance.
Conclusion: Average total assets must be taken from the gross balance-sheet figures, without the Assessing Officer's substitutions; the finding is in favour of the assessee.
Issue (iv): Whether, for A.Ys. 2017-18 and 2018-19, DSIR quantification in Form 3CL bound the tax authorities for weighted deduction, and whether unapproved expenditure could independently qualify under other scientific-research deduction provisions.
Analysis: Following the insertion of Rule 6(7A)(b) from 01.07.2016, DSIR was statutorily entrusted with quantifying expenditure eligible for weighted deduction under section 35(2AB). Tax authorities could not substitute their views for the technical determination of that expert authority. However, denial of DSIR approval for weighted deduction did not by itself determine eligibility under sections 35(1)(i), 35(1)(iv), and 35(2), whose conditions require independent examination.
Conclusion: The restriction of weighted deduction to DSIR-approved expenditure was sustained against the assessee, but the alternate claims under sections 35(1)(i), 35(1)(iv), and 35(2) were remitted for fresh determination; the finding is partly in favour of the assessee.
Final Conclusion: The Revenue's substantive challenges for A.Y. 2016-17 fail, while the assessee's claims for weighted deduction for A.Ys. 2017-18 and 2018-19 fail to that extent; independent eligibility of the alternate scientific-research claims remains to be determined afresh.
Scientific-research deductions depend on applicable DSIR requirements, while alternate claims require independent examination and Rule 8D uses gross assets.
For A.Y. 2016-17, approved in-house R&D expenditure could not be limited to the amount quantified in DSIR Form 3CL because the applicable provisions required facility approval, not item-wise or quantum certification. The balance additional depreciation on eligible assets used for less than 180 days could be claimed in the succeeding year. Under Rule 8D, average total assets must use gross balance-sheet figures rather than written down fixed-asset values and net current assets. From 1 July 2016, DSIR quantification governs weighted deduction under section 35(2AB), while claims under other scientific-research provisions require separate examination.
Weighted deduction for approved in-house research and development facilities - Additional depreciation on plant and machinery used for less than 180 days - Disallowance of exempt-income expenditure under the statutory formula - Alternative deduction for scientific research expenditure Weighted deduction for approved in-house research and development facilities - Prospective quantification of eligible research expenditure - Allowability of weighted deduction for expenditure on an approved in-house research and development facility where the expenditure claimed differed from that quantified by DSIR in Form No. 3CL - HELD THAT: - For 2016-17, neither section 35(2AB) nor Rule 6(7A), as applicable, required DSIR's quantification and approval of each item of expenditure as a condition for deduction; the statutory emphasis was on approval of the facility. Since the facility held valid approval and the expenditure was neither found nongenuine nor unrelated to scientific research, deduction could not be restricted merely because Form No. 3CL reflected a lower amount. The subsequent amendment requiring certification of eligible expenditure imposed an additional condition and operated prospectively. For 2017-18 and 2018-19, Rule 6(7A)(b), effective from 01.07.2016, statutorily entrusted DSIR with quantification of eligible expenditure in Form No. 3CL; the income-tax authorities could not substitute their view for the technical determination of that specialized authority. The Hon'ble Gujarat High Court in Principal CIT v. B.A. Research India Ltd. [2016 (6) TMI 853 - GUJARAT HIGH COURT] has elaborately explained that the DSIR is a specialized body having expertise in the field of scientific research and development and the requirements under the statutory scheme are highly technical in nature and have therefore been consciously entrusted to an expert body. While the Assessing Officer may verify the accounts and the eligibility of the claim from the standpoint of the Act, he cannot ignore or override the determination made by the prescribed authority on matters falling within its domain [Paras 42, 43, 44, 45, 51] The Revenue's challenge to the deduction for 2016-17 was dismissed; the disallowance of weighted deduction for 2017-18 and 2018-19 was upheld. Balance additional depreciation - Entitlement to the balance additional depreciation on eligible plant and machinery acquired in the preceding year and put to use for less than 180 days - HELD THAT: - We find that the controversy raised by the Revenue is no longer res integra. The Hon'ble Karnataka High Court in CIT v. Rittal India (P.) Ltd. [2016 (1) TMI 81 - KARNATAKA HIGH COURT] held that additional depreciation is a beneficial provision intended to encourage industrialization and that once the assessee satisfies the conditions prescribed under section 32(1)(iia), the balance 50% of additional depreciation, which could not be allowed in the first year because of the restriction contained in the second proviso, would be allowable in the immediately succeeding year. Additional depreciation is a one-time incentive, and the restriction to fifty per cent in the year of acquisition where the asset is used for less than 180 days regulates only the timing of allowance, not the subsistence of entitlement. As applicable to 2016-17, the third proviso to section 32(1) expressly allowed the balance in the immediately succeeding year; the judicial position also recognized that the amendment removed an anomaly and reflected the underlying legislative intent. [Paras 20, 21, 23] The assessee was entitled to the balance additional depreciation, and the Revenue's challenge was dismissed. Rule 8D computation of average total assets - Computation of the average total assets denominator for disallowance of interest expenditure relating to exempt income under Rule 8D - HELD THAT: - Rule 8D(2)(ii) mandates the average of total assets as appearing in the balance sheet. It does not permit replacement of gross fixed assets by their written down value or reduction of current assets by current liabilities. Such adjustments reduce the denominator and inflate the disallowance, and would impermissibly rewrite the statutory formula. [Paras 28, 29, 30, 31] Deletion of the additional disallowance was upheld and the Revenue's grounds were dismissed. Alternative deduction for scientific research expenditure - Alternative claims for deduction of revenue and capital scientific research expenditure excluded by DSIR from weighted deduction - HELD THAT: - Non-approval of expenditure by DSIR for weighted deduction under section 35(2AB) does not automatically disentitle the assessee to deduction under the distinct statutory provisions governing revenue scientific research expenditure and capital scientific research expenditure. As those conditions had not been independently examined, rejection of the alternative claims solely on account of DSIR non-approval was legally unsustainable. [Paras 46, 47, 51] For 2017-18 and 2018-19, the alternative claims were remanded to the Assessing Officer for fresh examination under the applicable provisions after opportunity of hearing. Final Conclusion: The Revenue's appeal for 2016-17 was dismissed. The assessee's appeals for 2017-18 and 2018-19 were partly allowed for statistical purposes, with the alternative scientific research deduction claims restored for fresh adjudication.